TRVI
Trevi Therapeutics Inc
NASDAQ · Pharmaceuticals
$11.46
+0.52 (+4.75%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 772.80M | 683.27M | 746.33M |
| Net Income | 98.54M | 104.02M | 99.75M |
| EPS | — | — | — |
| Profit Margin | 12.8% | 15.2% | 13.4% |
| Rev Growth | +0.7% | +7.7% | +15.7% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 717.28M | 699.31M | 738.29M |
| Total Equity | 1.12B | 1.05B | 1.05B |
| D/E Ratio | 0.64 | 0.66 | 0.70 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 196.14M | 177.32M | 185.79M |
| Free Cash Flow | 50.24M | 55.58M | 60.41M |